CFI writing to EMA to urge an earlier decision on Trikafta 

As our members know, the CFTR drug therapy Trikafta is currently under review by the European Medicines Agency (EMA). It was previously approved by the Food and Drug Administration (FDA) in the United States. 

While the precise date of when Trikafta will be approved by the EMA is still unknown, we previously predicted a decision by the EMA by Autumn/Winter 2020.

CFI has written today (2 April 2020) to the Head of the EMA to urge them consideration of earlier approval of Trikafta, if at all possible. An earlier than expected decision would be a boost to many people with CF who could potentially benefit from this groundbreaking drug in Ireland, particularly at this time. However it should be noted ultimate access by Irish patients to Trikafta will also be dependent on logistics/capacity/safety within our hospitals, which are presently under severe pressure with COVID-19.  

We will provide further updates on the journey of Trikafta, when further information is available.

CFI thanks all our CF teams for their work

CFI once again thanks our CF clinicians and their teams for all their fantastic work in supporting people with CF and in many cases, other patients with respiratory problems at this time. It is very much appreciated.